{
  "id": 3614,
  "text": "1605.Candelaria, M., et al.Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing plateletderived growth factor receptor alpha.Int $J$ Gynecol Cancer 19, 1632-1637 (2009).",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: 1605.Candelaria, M., et al.Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing plateletderived growth factor receptor alpha.Int $J$ Gynecol Cancer 19, 1632-1637 (2009).\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "根据研究，伊马替尼美司酸盐作为第二线治疗对于复发性或转移性宫颈癌患者，即使这些患者表达血小板来源生长因子受体α，其效果仍然有限。在2009年的一项研究中，研究者评估了伊马替尼在这类患者中的疗效，但结果显示其没有显著改善临床结局。这表明伊马替尼可能不适合作为复发性或转移性宫颈癌的有效治疗方案，尤其是在这些特定的分子标志物背景下。",
  "query": "在治疗复发性或转移性宫颈癌时，伊马替尼美司酸盐作为第二线治疗对于表达血小板来源生长因子受体α的效果如何？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在治疗复发性或转移性宫颈癌时，伊马替尼美司酸盐作为第二线治疗对于表达血小板来源生长因子受体α的效果如何？\n\n<reference text>: 1605.Candelaria, M., et al.Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing plateletderived growth factor receptor alpha.Int $J$ Gynecol Cancer 19, 1632-1637 (2009).\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "根据研究，伊马替尼美司酸盐作为第二线治疗对于复发性或转移性宫颈癌患者，即使这些患者表达血小板来源生长因子受体α，其效果仍然有限。在2009年的一项研究中，研究者评估了伊马替尼在这类患者中的疗效，但结果显示其没有显著改善临床结局。这表明伊马替尼可能不适合作为复发性或转移性宫颈癌的有效治疗方案，尤其是在这些特定的分子标志物背景下。"
}